You’re Invited: Beacon World Tour at a city near you! Learn More

Cell Line Development Application

The New Standard
for Speed, Monoclonality,
and Quality

Experience Unprecedented Speed in with the Cell Line Development Workflow

The Beacon® and Beacon Select™ optofluidic systems accelerate Cell Line Development (CLD), offering rapid cloning, screening, and selection of CHO cell lines.

Widely used by top pharmaceutical firms and CDMOs, these systems enhance workflow efficiency, allowing 4X faster throughput and halving development time while ensuring >99% monoclonality for FDA filings and higher titer clones.

Additionally, Opto™ Assure assays quickly identify quality clones, reducing costs and improving success rates during the scale up process.

Cell Line Development Application

Experience Unprecedented Speed

Measure antibody production from 1000s of clones
Enrich for top-secreting clones with favorable critical quality attributes
Recover top-secreting clones with high monoclonality assurance
Supported Instruments: Beacon, Beacon Select for CLD
Clone, Culture, Assay and Recover Top Clones on a Single Platform
Identify top producers with favorable product quality attributes within 5 days of cloning

CHO cell line selection is a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. The Opto® CLD workflow on the Beacon® and Beacon Select™ systems accelerates early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process. Hear about capabilities of on-chip detection that pinpoints the best clones early in the process.

Opto® Cell Line Development Workflow

Cell Line Development (CLD) on the Beacon® and Beacon Select™ optofluidic systems enables high throughput cloning, screening, and selection of top-performing CHO cell lines in just days.

Used globally by leading pharmaceutical companies and CDMOs, the Beacon systems’ industry-leading technology delivers unrivaled speed and efficiency to cell line development workflows. The Opto® CLD workflow has enabled customers to select clones with higher titers than traditional methods, increase throughput by 4X while reducing their cell line development timeline by up to 50%, and recover clones with >99% monoclonality assurance to support FDA IND regulatory filings (Application Note: FDA Accepted IND).

In addition, the Opto™ Assure quality assays enable users to select clones with favorable critical quality attributes within 5 days of cloning to reduce overall costs, improve the probability of success, and further shorten timelines by selecting the top clones for scale up.

Deliver the Best Cell Lines

Set your IND up for success by getting FDA-accepted monoclonality assurance in just days.

Customer Webinars
Workflow in Action
Thermo Fisher Scientific on:
“Leveraging Innovative Technologies to Accelerate Biologics Development”
Accelerate Cell Line Development

See how pioneers in Cell Line Development use our technology to speed up workflows.

Develop a Deeper Understanding
of Cell Line Development

Accelerate timelines and reduce costs

Select for even the most complex molecules in just days

Replace 8-12 weeks of onerous well plate steps with Opto® CLD on the Beacon® and Beacon Select™ optofluidic systems.​ Screen thousands of clones in parallel and select top clones for even non-traditional antibody molecules, like bispecifics.


Measure, Quantify, and Enrich

Selection Based on Product Quality, Not Just Productivity

​​Get to production faster with Opto™ Assure for early manufacturability assessment.​​

ASSAY FOR AGGREGATION: Opto™ Assure minimizes risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality. Opto Assure assay for aggregation enables direct detection of product aggregates within days of single cell cloning. This lets you confidently identify and select clones that secrete high-quality complex molecules and develop better production cell lines faster. ​​
Get >99% monoclonality assurance with a single, automated round of cloning.

The Bruker Cellular Analysis Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance – which is equivalent to four rounds of limiting dilution!

See independent validation by Le, K et al. Amgen.

Bulk stable pool to rare, top quality clones in one week​

Selective Cell Cloning with Opto CLD lets you screen up to 100,000 cells in a single 5-day workflow, enabling access to more relevant cell diversity than conventional methods for cell line development. Gently enrich transfected pools by identifying and cloning only cells that are viable and express your protein of interest. With Selective Cell Cloning, you can access broad genetic diversity by measuring bulk stable pools, all while eliminating weeks of mini-pool processing.

FDA-accepted clonality assurance for a successful IND​

The Beacon system’s optofluidic chip technology and the integrated imaging provide evidence of >99% monoclonality, without manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for evidence of monoclonality to support regulatory approvals.

Enable the selections of top clones over multiple days

The Opto CLD Workflow enables selection of top clones by measuring growth over multiple days of on-chip culture and secretion titers using quantitative assays for both traditional and non-traditional antibodies.

Measure antibody production from 1000s of clones
Enrich for top-secreting clones with favorable critical quality attributes
Recover top-secreting clones with high monoclonality assurance
Bruker Cellular Analysis' Functional Cell Biology Has Been Published in 100+ Publications
Research & Datasheets

Resource Type

Resource Type


Customer Spotlight
Catalent Biologics on Cell Line Development
How to Get More Molecules to the Clinic Faster with Automated Cell Line Development
The Opto® Cell Line Development Workflow
Cell Line Development on the Beacon Platform
Increase CDMO Revenue with the Opto Cell Line Development Workflow
Automated Cell Line Development on the Beacon® Platform
Beacon for Cell Line Development
Let’s Unleash the Full Potential of
Your CLD Research

Complete the form to connect with us and discover how the Beacon technology can enhance your CLD programs.

Our expert team will be able to answer your questions, show you how the Beacon system works, and share the most relevant datasheets & case studies for your research.